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Cyclooxygenase (COX) is the key enzyme in the conversion of arachidonic acid to prostaglandins. COX has two isoforms:
COX-1, the constitutively expressed form, and COX-2, the inducible form. Prostaglandins are mediators of many critical
physiological and inflammatory responses, but little is known about their roles during a viral infection in the central nervous
system (CNS). We used non-selective inhibitors of COX, aspirin and indomethacin, and a selective antagonist of COX-2,
celecoxib, to study the role of prostaglandins in Vesicular Stomatitis Virus (VSV) induced encephalitis. We found that the
inhibition of COX antagonizes VSV propagation both in vitro and in vivo. In addition, aspirin and celecoxib both prevented the
disruption of the blood brain barrier in VSV-infected mice. In vitro experiments showed that the effect of COX inhibition was
at least partially mediated by increased production of Nitric Oxide (NO), a molecule known to inhibit VSV replication. When
NO production was inhibited by Nv-nitro-L-methyl-arginine-ester (L-NAME), a nitric oxide synthase (NOS) inhibitor, the
difference in viral titer between aspirin (or celecoxib)-treated and the control cells was abolished. VSV-infected mice treated
with celecoxib expressed more NOS-1 and produced more NO in their CNS compared to the controls. Our data suggest that
oductiothe product(s) of COX have antagonistic effect(s) on NO pr
INTRODUCTION
Prostaglandins (PGs) are a group of hormone-like mol-
ecules formed from arachidonic acid. They are mediators
of many critical physiological responses, including blood
clotting, ovulation, bone metabolism, and kidney function
(Dubios et al., 1998). The production of PGs increases
dramatically during inflammation (Cao et al., 1999). PGE2
is the most abundant and potent PG produced during
inflammation. PGE2 has also been shown to be an im-
portant immunomodulator for cytokine profiles secreted
by T and B cells (Snijdewint et al., 1993).
COX is the rate-limiting enzyme in the production of
PGs. COX catalyzes the oxidation of arachidonic acid to
PGH2, which is subsequently isomerized and reduced to
he major biologically active eicosanoids, PGE2, PGF2a,
PGI2, and thromboxane A2 (TXA2). The array of PGs
produced varies depending on the down-stream enzy-
matic machinery present in a particular cell type. There
are two isoforms of COX: COX-1 and COX-2. While they
both have a similar size (71 KD), nearly identical enzyme
kinetics, and have 75% amino acid homology, COX-1 and
COX-2 are functionally different. COX-1 protein has been
detected in nearly all tissues (Crofford, 1997). It is con-
stitutively expressed and plays a housekeeping role
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(Palmer et al., 1995; Zambraski et al., 1995; Trevethick et
al., 1995). COX-2 is only constitutively expressed in brain.
It is dramatically induced during inflammation by cyto-
kines, mitogens, and phorbol esters (Kanner et al., 1992;
Stadler et al., 1993; Harbrecht et al., 1995).
Non-steroidal anti-inflammatory drugs (NSAIDs) have
long been used to treat fever and inflammatory diseases
such as arthritis. Vane showed that all NSAIDs inhibit
local prostaglandin production (Vane 1971). Traditional
NSAIDs like aspirin, ibuprofen, and indomethacin can
inhibit the activity of both COX isoforms. Although they
are very effective in ameliorating inflammation, they can
cause side effects. New generation NSAIDs, including
celecoxib (Celebrex) and rofecoxib (Vioxx), selectively
antagonize COX-2. They treat inflammatory diseases
without the side effects caused by non-selective NSAIDs
(Hamilton et al., 1999; McAdam et al., 1999).
Despite the extensive study of PGs, little is known
about their role(s) during a viral infection in CNS. We
have begun to use Vesicular Stomatits Virus (VSV)-in-
duced encephalitis as a model system to study the
role(s) of COX, especially COX-2. VSV is a member of the
Rhabodovirius family. It is an enveloped, single-stranded,
negative sense RNA virus (Wagner, 1987). Intranasal in-
stillation of VSV into mice leads to initial infection of
sensory neurons and retrograde transport to the CNS
(Plakhov et al., 1995). The host defense mechanism(s)
that control the neurotropic viral infection in the CNS and
mediate viral clearance are not fully understood. We
have shown that Nitric Oxide (NO) has a potent antiviral
effect for VSV both in vitro and in vivo (Bi and Reiss,
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HIBITI1995a; Komatsu et al., 1996; Komatsu et al., 1999a,b). NO
is produced from L-arginine by nitric oxide synthase
(NOS). NO has been demonstrated to be a key compo-
nent in host defense against a variety of pathogens
including protozoan parasites, fungi, bacteria, and vi-
ruses (Harris et al., 1995; Karupiah et al., 1993; Lee et al.,
1994; Seguin et al., 1994; Stenger et al., 1994). It has
inhibitory effects on replication of both DNA and RNA
viruses (reviewed by Reiss and Komatsu, 1998).
Several studies have described inflammation-induced
changes in the levels of PGE2 and NO. In murine mac-
rophages, it was shown that PGE2 either had a positive
Lin et al., 1999) or negative (Patel et al., 1999) effect on
O production under different conditions. PGE2 and NO
ay positively regulate each other in rat cerebral isch-
mia (Mogawa et al., 1998). Very little is known about the
elationship between COX and NOS, and hence PGs and
O, during a viral infection. COX-2 was found to be
levated in CNS in HIV associated dementia (Griffen et
l., 1994) and that it was involved in HIV-1–induced ap-
ptosis of neurons (Bagetta et al., 1998). NO is also
nduced during some CNS diseases (Adamson et al.,
996; Hooper et al., 1995; Komatsu et al., 1999a).
In the present study, we observed that both aspirin-
reated and celecoxib-treated neuroblastoma cell lines
nd infected mice produced more NO than the controls.
ubsequently, viral replication was inhibited.
RESULTS
ells treated with NSAIDs had lower viral production
nd increased NO output
To investigate whether the inhibition of COX activity
ad an effect on the VSV propagation, we initially tested
wo cell lines: a neuroblastoma cell line, NB41A3, and an
strocytoma line, C6. Both cells lines showed the same
esults, so only data collected from NB41A3 cells are
epresented. We pre-treated cells with either a non-se-
ective COX inhibitor, aspirin, or a selective COX-2 antag-
nist, celecoxib. Culture supernatant was collected 8 h
ost VSV infection. Analysis of the viral titers revealed
hat NSAID-treated cells produced less virus compared
o that of the control (Fig. 1A). PGE2 levels were tested by
ELISA to confirm inhibition of prostaglandin production
(Fig. 1B).
As an indication of NOS activity, NO2
2 (a stable end-
roduct of NO) concentration was measured. We found
ignificantly more NO2
2 in the supernatants of NSAID-
treated cells (Fig. 1C). Culture supernatants from unin-
fected cells treated with aspirin and celexocib were also
collected and checked for NO2
2 concentration; they
howed the same trends as infected cell supernatants
data not shown).
COX-2 is constitutively expressed and active in both
NSAID TREATMENT AND INB41A3 and C6 cells (data not shown). The inhibition of
G production might potentiate NOS activity. Celecoxib
d
dreatment inhibited viral production by 5–8-fold. Although
t is a relatively modest inhibition, the result was consis-
ently repeated in more than 10 independent experi-
ents. We believe that the modest effect may be due to
short incubation time (8 h) in tissue culture. We will
emonstrate below that when BALB/c mice were treated
FIG. 1. Viral titers were reduced when NB41A3 cells were treated
with NSAIDs. (A) NSAID-treated cells produced significantly less virus
(P , 0.05) (MED: media control, ASA: aspirin, CEL: celecoxib). (B) PGE2
production was inhibited by NSAIDs. (C) NSAID-treated cells produced
significantly higher NO (P , 0.05). NB41A3 cells were treated with
aspirin (5 mM), celecoxib (100 nM) or media for 24 h and then infected
with VSV at m.o.i. 0.01. Cell culture supernatant was collected at 8 h
post infection. Viral titers, PGE2 concentration and NO concentration
were determined individually. Each treatment was done in triplicate per
experiment. Similar responses were seen with C6 cells, data not
shown. Data represent results of one experiment. Similar trends were
seen in at least 3 replicate experiments.
45ON OF VSV PROPAGATIONaily with celecoxib for 6 days, there was a dramatic
ifference in viral titer.
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of NSAIDs on viral growth
NO inhibits VSV propagation (Bi and Reiss, 1995a;
Komatsu et al., 1996; Komatsu et al., 1999a,b), so the
ncreased NO production from NSAID-treated cells may
e the reason why viral propagation was diminished. To
est this hypothesis, we used a NOS substrate analog,
v-nitro-L-Methyl-Arginine-ester (L-NAME) to inhibit the
O production. When L-NAME was added at the same
ime with NSAIDs to the cells, NO production was re-
uced (Fig. 2B). Viral titers in the NSAID and L-NAME
ouble-treated cells increased (Fig. 2A). Thus, the likely
ffector molecule of the antiviral activity in NSAID-treated
euronal cells is NO.
ddition of PGE2 increased viral titer
FIG. 2. NOS antagonist L-NAME abolishes the NSAID’s effect on viral
growth. (A) L-NAME raised the viral titers in the NSAIDs treated cells
(MED: media control, ASA: aspirin, CEL: celecoxib). (B) L-NAME- and
NSAID-double treated cells produced NO at a much lower level com-
pared with cells treated with NSAIDs alone (P , 0.05, when comparing
L-NAME- and NSAID-double treated cells and NSAID treated alone).
NB41A3 cells were treated with aspirin (5 mM), celecoxib (100 nM) or
media for 24 h and then infected with VSV at m.o.i. 0.01. L-NAME was
added at the same time with NSAIDs. Cell culture supernatant was
collected at 8 h post infection. Viral titers and NO concentration were
determined individually. Each treatment was done in triplicate per
experiment. Similar responses were seen with C6 cells, data not
shown. Data represent results of one experiment. Similar trends were
seen in at least 3 replicate experiments.
46 CHEN, WARPGE2 is the major prostaglandin produced in the CNS
during inflammation (Fontata et al., 1982; Hartung andToyka, 1987; Appleton et al., 1996). If the effect of NSAIDs
on viral growth is a result of their ability to inhibit pros-
taglandin production, and not due to some other bio-
chemical pathway, supplementation of culture medium
with PGE2 should reverse the effect of NSAID treatment.
1028M of PGE2 was added to either NB41A3 or C6 cells.
Cells double-treated with PGE2 and NSAID produced a
igher VSV yield than NSAID-treated cells (Fig. 3A). In
ells receiving exogenous PGE2, less NO was produced
Fig. 3B). The level of virus produced in the presence of
xogenous PGE2 did not reach the titer found in control
cells. It could be that besides PGE2, other prostaglandins
also played role(s) in mediating this effect, or that the
functional local concentration of PGE2 in the cytoplasm
of infected cells exceeded that achieved by our supple-
mentation.
Effects of NSAID treatment on VSV infected mice
COX-2 has been localized to some neurons, astro-
cytes, and endothelial cells in the CNS (Hewett, 1999;
FIG. 3. Exogenous PGE2 increased viral titer in NB41A3 cells treated
with NSAIDs. (A) PGE2 increased viral titers significantly in NSAID-
treated cells. (B) PGE2 lowered the NO production in NSAID-treated
ells (P , 0.05). NB41A3 cells were treated with 10-8M PGE2 and
infected with VSV at m.o.i. 0.01. Viral titers and NO production were
examined in the culture supernatant 8 h post infection. Each treatment
was done in triplicate per experiment. Similar responses were seen
ND REISSwith C6 cells, data not shown. Data represent results of one experi-
ment. Similar trends were seen in at least 3 replicate experiments.
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HIBITIDeininger and Schluesener 1999; Beiche et al., 1998). Its
expression (or PG production) was reported to be ele-
vated in fever (Cao et al., 1999), ischmeric lesions
(Nogawa et al., 1998), and Multiple Sclerosis (Bolton et
l., 1984; Dore-Duff et al., 1986). To determine whether
he inhibition of COX had effect on VSV encephalitis in
ice, groups of BALB/c mice were infected intranasally
ith VSV, and were treated with aspirin, indomethacin,
elecoxib, or saline daily. Six individual mice per group
ere examined at Day 3 or Day 6 post infection for viral
iter in CNS homogenates. NSAID-treated mice had as
uch as 100-fold lower viral titers in their CNS than
aline-treated mice at Day 6 post infection (Fig. 4A).
The integrity of blood brain barrier (BBB) is another
ood indication of VSV pathology and a prognostic indi-
ator for survival (Bi et al., 1995b). The BBB of infected
xperimental animals was assessed by exclusion of
vans Blue Dye; the BBBs of VSV-infected, NSAID-
reated mice were better preserved than saline-treated
ice (Fig. 4B). NSAID treatment of uninfected mice did
ot disrupt the BBB (data not shown).
NOS-1 has been shown to be the key enzyme to
estrict VSV propagation in the CNS (Komatsu et al.,
999a). NOS-1 expression and activity in the mouse CNS
as examined. Immunohistochemical staining showed
hat celecoxib-treated mice had more frequent and in-
ensely staining NOS-1 expressing neurons (Fig. 5A).
rains from mice treated with celecoxib or media were
lso checked for of NO production; no significant differ-
nce between the celecoxib and media group could be
etected in uninfected donors, but the level of NO2
2
present was twice that of media-treated VSV-infected
mice at three days p.i. (Fig. 5B). Therefore inhibition of
COX-2 by celecoxib resulted in increased NO production,
suppressed viral replication, and increased integrity of
the BBB.
DISCUSSION
A high output of PGs and NO is one of the hallmarks
of inflammation. However, dynamic interactions between
COX and NOS in the milieu of inflammation are not well
understood. Their relationship is even less known in the
CNS, which has been traditionally considered to be an
immunologically privileged site. The action(s) of these
small molecules within the infected neurons may have
an impact on the pathogenesis of viral encephalitis,
especially given that NO is an important anti-viral agent
(reviewed by Reiss and Komatsu, 1998).
NSAID-treated cells are more resistant to viral infec-
tion (Fig. 1). Both the nonselective COX inhibitor aspirin
and the COX-2-selective antagonist celecoxib reduced
viral yield in vitro significantly. Aspirin-treated cells pro-
duced less virus than celecoxib-treated cells; it could be
NSAID TREATMENT AND INattributable to a) aspirin’s ability to inhibit both COX-1
and COX-2 isoforms, b) irreversible acetylation of theenzymes by aspirin, or c) aspirin-mediated effect on
another pathway, which may affect viral production (Yin
et al., 1998).
The inhibition of prostaglandin synthesis was associ-
ated with an increased NO production (Fig. 1). NO is a
well-documented viral restriction molecule. NOS-1 ex-
pression correlated with restriction of VSV propagation in
mouse CNS (Komatsu et al., 1999a). The addition of the
NOS inhibitor L-NAME to cell culture confirmed our hy-
FIG. 4. Viral titers were reduced in the NSAID-treated mice CNS. (A)
NSAID-treated mice had much lower viral titers in CNS than the control
group (P , 0.05, at Day 3 pi only Indomethacin treated mice showed
ignificant difference, at Day 6 pi, both NSAID treated mice had signif-
cant lower virus in their CNS compared to media control) (MED: 0.9%
aline control, Indo: Indomethacin, Cel: celecoxib). (B) NSAID-treated
ice had much better preserved BBB than the control group (P , 0.05).
ll experiments were done twice. (W/O Evans Blue: brains from unin-
ected mice that were not injected with Evans Blue, W/O VSV: Brains
rom uninfected mice that were injected with Evans Blue. VSV1Med:
rains from infected mice treated with saline and injected with Evans
lue, VSV1ASA: Brains from infected mice treated with aspirin and
njected with Evans Blue, VSV1Cel: Brains from infected mice treated
ith celecoxib and injected with Evans Blue.) BALB/c mouse were
nfected with VSV (intranasally, 2 3 105 pfu) and pi injected with aspirin
100 mM), Indomethacin (10 mg/kg) or celcoxib (5 mM) every day. For
viral titer experiment, On Day 3 or 6 pi 6 mice from each group were
sacrificed and the mouse brains were homogenized for determination
of viral titers on CHO cells. For BBB experiment, 3 mouse brains were
examined from each group at Day 8 pi to determine the degree of BBB
disruption.
47ON OF VSV PROPAGATIONpothesis that the beneficial effect of NSAID-treatment on
viral growth was through a NO-mediated pathway (Fig.
ph
n
n
S
p
e
t
u
e
m
r
N
t
t
p
(
s
b
T
b
o
e
s
s
a
r
t
i
m
l
a
a
s
s
g
c
t
B
t
w
(
d
c
g
NER, A2). The addition of PGE2 to cultures both diminished NO
production and increased the viral yields (Fig. 3). This
was consistent with the interpretation that PGs antago-
nize the production of NO, and that NO was the factor
that inhibited VSV replication. Another interesting obser-
vation is that in L-NAME-treated cells, more PGE2 was
resent than the media-treated cells (data not shown).
Numerous studies using peripherally derived cells
ave demonstrated that in certain cell types, endoge-
ous and/or exogenous NO inhibited COX activity (Kan-
ar et al., 1992; Stadler et al., 1993; Harbrecht et al., 1995;
wierkosz et al., 1995). Our observations suggest that the
roduct(s) of COX and NOS might have antagonistic
ffects on each other in neuronal cell lines. At this time,
he mechanism for the inhibition of NOS by PGs is still
ndefined. The NO inhibition of COX could be more
asily explained. NO or ONOO2 may directly interact
with tyrosine and cysteine residues in COX, thus inacti-
vating the enzyme. A recent paper by Clancy et al. (2000)
demonstrated that in macrophages, the capacity of NO to
inhibit PGE2 release is associated with a decrease in
COX-2 expression as well as nitration of the enzyme. A
model of the proposed interactions between COX, NOS,
and the impact on viral infection is illustrated in Fig. 6.
VSV-infected mice treated with NSAIDs had lower viral
FIG. 5. Celecoxib-treatment increased NOS-1 expression and activity
in vivo. (A) Celecoxib-treated mice had more NOS-1 expressed in their
CNS. Pictures showed were the region of olfactory bulb. (B) When
infected with VSV, celecoxib-treated mice produced more NO in their
CNS (P , 0.01). For immunohistochemical staining, each group had
hree mice. Mice were sacrificed at Day 7 post infection, their brains
ere taken out and sectioned separately to stain for NOS-1 expression.
See Materials and Methods) Quantitation of NOS activity in CNS was
one by the Greiss assay. Homogenates from media-treated or Cele-
oxib-treated uninfected or VSV-infected brains from 6 individuals/
roup were assayed for NO2
2 content.
48 CHEN, WARtiters in their CNS. Although the environment in vivo is
uch more complex than that of tissue culture, it iseasonable to extrapolate that the antagonism between
OS and COX may exist and potentially play an impor-
ant role during the inflammation in the CNS. The fact
hat celecoxib-treated mice expressed more NOS-1 and
roduced more NO strongly supports this hypothesis
Fig. 5). NO inhibition of viral infection, while not univer-
al, is documented for roughly half of the viruses studied,
oth in vitro and in vivo (Reiss and Komatsu, 1998).
hus, NSAID treatment early in viral infection could be
eneficial.
We still have to take into consideration that inhibition
f PG production could result in profound systematic
ffect(s) which could increase NOS activity. In vitro, PGE2
was shown to suppress Th1 responses; it could selec-
tively, and in a dose dependent manner, inhibit IFN-g
production by stimulated human T cells (Snijdewint et al.,
1993). PGE2 could down-regulate IL-12 receptor expres-
ion in astrocytes (Wu et al., 1999). In vivo, PGE2 was also
hown to suppress the production of Th1 cytokines such
s IL-12 (Newberry et al., 1999). A recent paper by Ku-
oda et al. (2000) showed that treatment with NS-398,
another COX-2 selective inhibitor, can promote the Th1
immune response in BALB/c mouse. Stolina et al. (2000)
demonstrated that treatment with a COX-2 inhibitor re-
stored antitumor reactivity by promoting IL-12 production.
Taken together, PGE2 production could impede hosts
from developing a Th1response. Th1 effector cells and
cytokine production have been shown to be crucial fac-
tors in restricting VSV propagation (Komatsu et al., 1998).
So excessive PGE2 produced during VSV associated
inflammation could potentially harm the host. On the
other hand, inhibition of PGE2 production was observed
o be beneficial.
Another important observation in this study is that the
nhibition of COX can protect the BBB of the infected
ice from pathological disruption (Fig. 4B). COX-2 is
ocalized to endothelial cells constituting the BBB, large
mount of prostaglandins produced during inflammation
re potent vasodilators. Prostaglandins may by them-
elves cause BBB to break or work through some down-
tream amplifier pathways, such as vascular endothelial
rowth factor (VEGF), a highly specific mitogen for vas-
ular endothelial cells and strong stimulator of vasodila-
ion (Ben-Av et al., 1995). Exploring the mechanism(s) of
BB breakdown is beyond the scope of this paper. We
ND REISSFIG. 6. Model of the proposed interaction between COX and NOS.
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HIBITIhave shown that, COX-2 may be a crucial factor in this
complicated process. This observation has profound
clinical implications for drug delivery across the BBB
during infection or to treat brain tumors.
In summary, we have presented evidence that inhibi-
tion of PGE2 production can diminish viral yield and this
ffect was at least partially mediated by the enhanced
roduction of NO. Although the relationship might not be
irect, COX and NOS have inhibitory effects on each
ther. A clear understanding of the molecular mecha-
isms that regulate COX-2 expression and activity and
ownstream pathways during a viral infection may lead
o the development of novel treatments for both infection
nd inflammation.
MATERIALS AND METHODS
irus and cells
VSV Indiana serotype, San Juan strain, was propa-
ated in Chinese Hamster Ovary (CHO) cells and purified
wice using a sucrose gradient. NB41A3 neuroblastoma
ells and C6 astrocytoma cells were obtained from
TCC. CHO cells and VSV isolates were originally ob-
ained from Dr. Alice S. Huang.
nfection with VSV and treatment with NSAIDs
In vitro. Cells (105/ml) were cultured in 24-well plates
ith NSAIDs (5 mM aspirin or 100 nM celecoxib) for 24 h.
t the end of 24 h, the cells were either mock infected
ith HBSS or infected with VSV (m.o.i. 0.01). Cells were
hen cultured with or without NSAIDs (5 mM aspirin or
00 nM celecoxib) for 8 h at which time supernatants
ere collected. To inhibit NOS activity, L-NAME was
sed at 500 mM and added at the same time as NSAIDs.
In vivo. Specific pathogen-free male BALB/c AnTac
ice, 5–7 weeks old were obtained from Taconic (Ger-
antown, NY). Mice were lightly anesthetized for 1 min
n a closed chamber containing isofluorane, followed by
ntranasal infection with 105 pfu of VSV in a total volume
f 0.01 ml 0.9% saline (Bi and Reiss, 1995a). Aspirin (100
g/kg), Indomethacin (10 mg/kg), celecoxib (5 mg/kg) or
.9% saline were injected ip every day until mice were
acrificed. At each time point (Day 3 or Day 6 post
nfection), 6 mice in each group were sacrificed. Brains
ere removed and individually homogenized to deter-
ine viral titer in CNS.
etermination of viral titer
Viral titers were determined on monolayer of CHO
ells as previously described (Huneycutt et al., 1993).
HO cell monolayers were prepared by inoculating 5 3
05 cells/well in 24-well plates for 5 h at 37°C. The
medium was removed, 0.1 ml of each dilution of samples
NSAID TREATMENT AND IN(10-fold serial dilutions) was added to each well, in du-
plicate, and the wells were then incubated for 30 min at37°C. The medium was removed, 1 ml of the mixture of
equal volumes of 1.8% agar (kept at 45°C) and 2X culture
medium (kept at 37°C) was added to each well, and the
wells were then incubated at 37°C for 22 h. Plaques
were fixed with 10% formaldehyde for 30 min and stained
with 0.5% methylene blue.
Determination of NO concentration
The concentration of NO in culture supernatant was
determined by assaying its stable end product, NO22, as
reviously described (Bredt et al., 1989). Briefly, equal
olumes of experimental sample and Greiss reagent (1%
ulfanilamide, 0.1% N-1-naphthyl-ethylene-diamine, and
% H3PO4; Sigma Chemical Co.) were incubated at room
emperature for 10 min. The reaction produces a pink
olor, which was quantified at 540 nm by an automated
late reader. (Bio-Rad, Inc., model 550).
etermination of PGE2 concentration
PGE2 level was detected by ELISA, following the
instructions provided by the manufacture (Cayman
Chemical).
Evaluation of BBB breakdown
On the experimental day, three mice from each group
were injected intravenously with 200 ml of 2% Evans
Sigma). One hour later, mice were sacrificed with a
ethal dose of avertin and transcardially perfused with
aline. Brains were removed. Evans blue dye uptake was
xtracted by putting brain in a test tube containing for-
amide and incubating them for 72 h, then optical den-
ity of formamide was measured at 620 nm (Kakinuma et
l., 1998).
mmunohistochemical staining
Brains were sectioned (14 mm sections) in the sagittal
orientation using a cryostat. Sections were stained as
previously described (Bi et al., 1995b). NOS-1 antibody
was purchased from Transduction labs.
Statistical method
Student’s t test was used in all statistical analyses. All
data were presented in mean 6 SEM.
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